Hims & Hers launched the Hims & Hers Multi-Cancer Test by Galleri on February 4, 2026, a blood test from GRAIL that screens for over 50 types of cancer before symptoms appear.256
The test is available as an add-on to Hims & Hers Labs plans at a $250 discount from Galleri's list price and complements standard screenings.26
GRAIL submitted its FDA Premarket Approval application for Galleri on January 29, 2026, supported by PATHFINDER 2 and NHS-Galleri trials; the test is not yet FDA-approved and requires a prescription.4
Recommended for adults 50+ with elevated risk; it detects cancer signals and predicts origin but may have false positives/negatives and does not detect all cancers.2
Partnership aims to increase access via Hims & Hers' telehealth platform.13
Sources:
1. https://pharmaphorum.com/news/grail-multi-cancer-test-taps-hims-hers-network
2. https://www.investing.com/news/company-news/hims--hers-launches-multicancer-blood-test-screening-for-50-cancers-93CH-4485157
3. https://firstwordhealthtech.com/story/7093378
4. https://grail.com/press-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/
5. https://investors.hims.com/news/news-details/2026/Hims--Hers-Launches-Multi-Cancer-Early-Detection-Testing-Connecting-Customers-to-Cutting-Edge-Proactive-Care/default.aspx
6. https://news.hims.com/newsroom/do-more-by-knowing-more-the-hims-hers-multi-cancer-test-by-galleri-r